A Phase 1b Study of Pembrolizumab (KEYTRUDA) in Combination With REOLYSIN (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Trial Profile

A Phase 1b Study of Pembrolizumab (KEYTRUDA) in Combination With REOLYSIN (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Pelareorep (Primary) ; Pembrolizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 08 Feb 2018 Planned end date changed from 1 Mar 2018 to 1 Dec 2018.
    • 08 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Oct 2018.
    • 20 Jan 2018 Results (n=11) assessing safety and efficacy of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy (gemcitabine or irinotecan or fluorouracil) in patients with advanced pancreatic adenocarcinoma, were presented at the 2018 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top